U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
(Exact name of small business issuer as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer ID No.) |
| (Address of principal executive offices) | (Zip Code) |
(
(Issuer’s Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Securities registered pursuant to Section 12(g) of the Act:
| Title of each Class | Trading Symbol | Name of Each Exchange on Which Registered |
| OTC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Material Event |
On September 30, 2022, Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., announced that it has decided to dissolve its sports advisory board.
| Item 7.01 | Regulation FD Disclosure |
Attached is a copy of a press release being issued by the Company relating to the above-referenced matter, a copy of which is attached as Exhibit as 99.1 and is hereby incorporated.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits.
| Number | Exhibit |
| 99.1 | Press Release |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Odyssey Group International, Inc. | ||
| By: | /s/ Joseph Michael Redmond | |
| Joseph Michael Redmond Chief Executive Officer | ||
Date: September 30, 2022
| 2 |
Exhibit 99.1
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) Odyssey Health, Inc. (OTC:ODYY), f/k/a Odyssey Group International, Inc., (the “Company” “Odyssey”) a company focused on developing a unique drug to treat concussion has decided to dissolve its sports advisory board.
The sports advisory members have been outspoken advocates for concussion prevention and for the importance of finding responsible treatments. We created the advisory board to increase awareness of our mission to bring a much-needed pharmaceutical for a condition that currently has no FDA approved treatment. We have recently completed a Phase I human trial where our drug was proven to be safe and well tolerated. We are excited about the potential of initiating a Phase II trial to determine the efficacy and safety of the drug in concussed patients.
The press has misrepresented Odyssey Health, Inc. Odyssey has never directly or indirectly received money from state or federal government sources to fund the drug development. Odyssey Health, Inc.purchased the intellectual property and rights to the drug on March 1, 2021. The money to fund the drug development has come from accredited investors. The Company contacted the press to advise of the facts and misstatements.
In order to keep our focus, the Company has decided to dissolve the sports advisory board, as it has caused distraction to our critical work being done. Odyssey wants to continue its focus on this important drug candidate in hopes of providing a much-needed treatment. The Company will remain committed to bringing products to market that provide a solution to unmet medical needs.
About Odyssey Health Inc. (formerly Odyssey Group International,
Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate
mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful
medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility,
and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com.
We encourage our shareholders to visit our corporate social media accounts
for updates:
https://twitter.com/OdysseyHealth1
https://www.facebook.com/odysseyhealthinc
https://www.linkedin.com/company/odysseyhealthinc
https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q
About PRV-002
PRV-002 is a fully synthetic, non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical
studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models
of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment,
anxiety and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate
swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and
uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase II trial, our ability to successfully
develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments
and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
Cover |
Sep. 30, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 30, 2022 |
| Entity File Number | 000-56196 |
| Entity Registrant Name | ODYSSEY HEALTH, INC. |
| Entity Central Index Key | 0001626644 |
| Entity Tax Identification Number | 47-1022125 |
| Entity Incorporation, State or Country Code | NV |
| Entity Address, Address Line One | 2300 West Sahara Avenue, Suite 800 - #4012 |
| Entity Address, City or Town | Las Vegas |
| Entity Address, State or Province | NV |
| Entity Address, Postal Zip Code | 89102 |
| City Area Code | 702 |
| Local Phone Number | 780-6559 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Trading Symbol | ODYY |
| Title of 12(g) Security | Common Stock ($0.001 par value) |
| Entity Emerging Growth Company | false |